Fisher Scientific to Acquire Athena Diagnostics from Behrman Capital and Purchase 9 Percent of Nanogen
Company Expands Presence in Molecular Diagnostics
Fisher Scientific International Inc. announced two transactions that will significantly enhance its capabilities in molecular diagnostics. Fisher has entered into a definitive agreement to acquire privately held Athena Diagnostics, Inc., developer and provider of proprietary molecular diagnostic and immunodiagnostic tests and services, from Behrman Capital for $283 million in cash. Athena has an extensive portfolio of proprietary neurologic, nephrologic and endocrine diagnostic tests targeting such diseases as neurogenetic and neuromuscular disorders as well as Alzheimer's disease, multiple sclerosis, obesity, kidney disease and diabetes. The company had 2005 net revenues of $55 million.
Fisher will fund the acquisition with cash-on-hand. The transaction, which is subject to customary closing conditions, is expected to close early in the second quarter. Fisher expects it will have no effect on its 2006 earnings per share and will be slightly accretive to cash earnings per share.
Simultaneous with its acquisition of Athena, Fisher has entered into an agreement to purchase 9 percent of Nanogen, Inc. for $15 million in cash. Nanogen is a provider of advanced molecular diagnostic equipment, microarrays and reagents for diagnostic applications. Fisher and Nanogen will collaborate to expand the use of Athena's proprietary markers and tests.
Most read news
Topics
Organizations
Other news from the department business & finance
These products might interest you

Milli-Q® Services / MyMilli-Q™ by Merck Life Science
Services & Support for Water Purification Systems
Quality Care, Delivered. In Person & Online

Good Weighing Practice by Mettler-Toledo
Your Concrete Weighing Quality Assurance Plan
GWP Verification service

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Researchers successfully develop animal free methods for testing chemical compounds for allergens - EU-funded research project developing in vitro test strategies to reduce or replace animal testing use gene expression analysis software
Laser diodes versus LEDs
Rubber Excellence Partnership with DIK and Qingdao University
Scientists show there's nothing boring about watching paint dry
Bayer MaterialScience LLC relocates polycarbonate film production
Strategic Analysis of the World Laboratory Information Management Systems (LIMS) Markets
Varian, Inc. Secures Strategic Patents for Key Technologies

Swiss cheese crystal, or high-tech sponge?
